The intervention group was 4.2 times more likely to use GLP-1 RAs for patients with T2D than the comparison group, controlling for the number of total patients with T2D, being an endocrinologist, and prior use of GLP-1 RAs (Table 1). The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.